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ABSTRACT
Purpose The purpose of this study was to gain insight into the
delivery and immunogenicity of N-trimethyl chitosan (TMC)
adjuvanted diphtheria toxoid (DT) formulations applied trans-
cutaneously with microneedles.
Methods Mice were vaccinated with DT-loaded TMC nano-
particles, a solution of TMC and DT (TMC/DT) or DT alone.
The formulations were applied onto the skin before or after
microneedle treatment with two different 300-µm-long micro-
needle arrays and also injected intradermally (ID). As a positive
control, alum-adjuvanted DT (DT-alum) was injected subcuta-
neously (SC). Ex vivo confocal microscopy studies were
performed with rhodamine-labelled TMC.
Results Independent of the microneedle array used and the
sequence of microneedle treatment and vaccine application,
transcutaneous immunisation with the TMC/DT mixture
elicited 8-fold higher IgG titres compared to the TMC
nanoparticles or DT solution. The toxin-neutralising antibody
titres from this group were similar to those elicited by SC DT-
alum. After ID immunisation, both TMC-containing formula-
tions induced enhanced titres compared to a DT solution.
Confocal microscopy studies revealed that transport of the
TMC nanoparticles across the microneedle conduits was
limited compared to a TMC solution.
Conclusions In conclusion, TMC has an adjuvant function in
transcutaneous immunisation with microneedles, but only if
applied in a solution.
KEY WORDS diphtheria toxoid . microneedles .
nanoparticles . transcutaneous immunisation . trimethyl chitosan
(TMC)
INTRODUCTION
Transcutaneous immunisation (i.e. immunisation through
vaccine application onto the skin) has the potential to be an
excellent non-invasive vaccination route (1). This is desirable
as injection of a vaccine with a needle and a syringe is not
only painful (2), but it also bears a risk of transmission of
infection with, e.g., hepatitis B or C, or human immunode-
ficiency virus (3). Furthermore, the skin is densely populated
with antigen presenting cells (APCs) (4). In the epidermis the
Langerhans cells (LCs) are present, and in the dermis the
dermal dendritic cells (DCs) (5,6). The main function of these
professional APCs is to sample their environment, process
antigens and present specific epitopes to T cells. Studies
using intradermal (ID) immunisation (i.e. injection of the
antigen into the dermis) have shown that this delivery route
can result in similar or even enhanced immune responses
compared to intramuscular immunisation (7,8).
During recent years, particle-based immunisation has
gained more emphasis (9). The advantage of nanoparticles
is that they can function as a depot (10) and are more
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efficiently taken up by DCs than plain antigens (11).
Therefore, nanoparticles may function as an adjuvant.
Nanoparticles can be prepared from polymers, such as poly
(DL-lactic-co-glycolic acid) (PLGA) or N-trimethyl chitosan
(TMC). TMC is a derivate of chitosan that bears a
permanent positive charge and is therefore water soluble
over a wide pH range. TMC nanoparticles have mainly been
used in mucosal immunisation (12–14), but recently we
showed that TMC can also function as an immune
potentiator in ID immunisation (15). Interestingly, we
observed that the adjuvant effect could be ascribed primarily
to the TMC polymer itself rather than to its formulation in
nanoparticles. After ID injection of diphtheria toxoid (DT)-
loaded TMC nanoparticles or a solution of TMC and DT
(TMC/DT mixture), mice developed 4-fold higher IgG titres
compared to those induced by plain DT. These results
indicate that in ID vaccination, antigen-loaded TMC nano-
particles are not superior to soluble TMC/antigen mixtures,
in contrast with, e.g., intranasal vaccination (16,17). This might
be attributed to the fact that with ID injection, antigen and
adjuvant are immediately delivered to an APC-rich environ-
ment, thereby making nanoparticles unnecessary.
Transcutaneous vaccination differs from ID vaccination
in that the antigen first has to be transported into the skin.
Only then can it be taken up by skin resident APCs and
induce APC maturation. The natural function of the skin is
to protect the body from the environment (18). This
function is exerted by the upper part of the epidermis, the
stratum corneum. Even though this part is only 15 µm thick
in human skin, it proves to be an excellent barrier. One
way to breach this barrier is by using microneedles. The
idea of using microneedles for transdermal drug delivery
dates back to 1971 (19), but only in the 1990s the first
microneedles were developed (20). Since then, their usage
has increased, and many different microneedles have
become available. Some devices are currently being tested
in clinical trials (21), and several others are in pre-clinical
development (22–24). The use of microneedles for vaccine
delivery can be based on different principles: hollow
microneedles can be used for injection of liquids; solid
microneedles can either be coated with the antigen of
interest or used for perforation of the skin prior to vaccine
application. The main advantage of microneedles is that
they are long enough to penetrate the stratum corneum,
but short enough to avoid pain and major discomfort
(25,26). During the past few years, we have been studying
solid microneedle arrays to pre-treat the skin, followed by
vaccine application. In previous studies, our group showed
that microneedle pre-treatment significantly increased
antibody titres in transcutaneous vaccination studies with
DT (27,28).
In this study, we will focus on the transport of DT-
loaded TMC nanoparticles and TMC/DT mixtures into
the skin by applying them as liquid formulations in combina-
tion with two types of solid microneedles. Immunisation
studies in mice were employed to compare the antibody
responses elicited by microneedle-based delivery to ID
delivery. To visualise the transport of soluble and particulate
TMC into the skin, the adjuvant was fluorescently labelled,
and confocal microscopy studies were performed.
MATERIALS AND METHODS
Materials
Chitosan (MW 120 kDa) with a degree of deacetylation of
92% was obtained from Primex (Alversham, Norway).
Cholera toxin (CT), pentasodium tripolyphosphate (TPP),
N-(2-hydroxyethyl) piperazine-N′-(2-ethanesulphonic acid)
(HEPES) and rhodamine B isothiocyanate were obtained
from Sigma Aldrich (Zwijndrecht, The Netherlands).
Diphtheria toxin (DTa 79/1) and DT (batch 98/40,
protein content 12.6 mg/ml by BCA assay, 1 μg equal to
approximately 0.3 Lf) were a kind gift from the Netherlands
Vaccine Institute (NVI, Bilthoven, The Netherlands).
Horseradish peroxidase (HRP) conjugated goat anti-
mouse IgG (γ chain specific), IgG1 (γ1 chain specific) and
IgG2a (γ2a chain specific) were purchased from Southern
Biotech (Birmingham, USA). Chromogen 3, 3′, 5, 5′-
tetramethylbenzidine (TMB) and the substrate buffer were
purchased from Invitrogen (Breda, The Netherlands).
Nimatek® (100 mg/ml Ketamine, Eurovet Animal Health
B.V., Bladel, The Netherlands), Oculentum Simplex
(Farmachemie, Haarlem, The Netherlands), Rompun®
(20 mg/ml Xylazine, Bayer B.V., Mijdrecht, The
Netherlands) and the injection fluid (0.9% NaCl) were
obtained from a local pharmacy. All other chemicals
were of analytical grade.
Animals
Female BALB/c mice (H2d), 8 weeks old at the start of the
vaccination study and male hairless (skh-1) mice, 7–9 weeks
old were purchased from Charles River (Maastricht, The
Netherlands) and maintained under standardised condi-
tions in the animal facility of the Leiden/Amsterdam
Centre for Drug Research, Leiden University. The study
was carried out under the guidelines compiled by the
Animal Ethic Committee of the Netherlands.
Vaccine Formulations
TMC with a degree of quarternisation of 15% was
synthesised from chitosan in a one-step methylation
reaction as described previously (15). The LPS content of
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TMC was found to be below the detection limit
(<0.1 ng/ml for 1 mg/ml TMC) when tested on TLR-
4 transfected HEK cells (data not shown). For confocal
microscopy studies, the TMC was labelled at the amine
group with rhodamine B isothiocyanate. TMC was
dissolved in a 0.1 M carbonate buffer pH 9, and
rhodamine B isothiocyanate was added in a TMC:
rhodamine ratio of 15:1. After subsequent dialysis in
1% NaCl and water until no rhodamine could be
detected in the dialysis solution (measured by fluores-
cence), the TMC-rhodamine solution was freeze dried.
TMC nanoparticles were prepared by ionic complex-
ation with TPP. A TMC:TPP (w/w) ratio of 6.7:1 was
used as described before (15). Briefly, for the preparation
of DT-loaded nanoparticles, 1 mg of DT was added to a
5 mM HEPES pH 7 solution containing 10 mg TMC.
After addition of TPP and 1 h of stirring, the nanoparticle
suspension was centrifuged for 15 min at 10,000 g on a
glycerol bed. The pellet was resuspended in 10 mM
phosphate buffer adjusted to pH 7.4. The size of the
nanoparticles was determined by dynamic light scattering
(DLS), and the zetapotential was determined by laser
Doppler velocimetry using a Zetasizer® Nano ZS (Mal-
vern Instruments, UK). The amount of DT in the
particles was measured with a micro-BCA protein assay
(Pierce, Rockford, IL, USA). TMC/DT mixtures were
prepared by mixing them in a 2.5:1 (w/w) ratio. To further
potentiate the immune response in some cases, CT was
added to the formulations in a DT:CT ratio of 1:1 (w/w)
just before usage. Finally, DT adsorbed to aluminium
phosphate (Adju-Phos®; Brenntag Biosector, Denmark)
(DT-alum) was prepared in a DT:alum ratio of 1:30 as
previously described, and the adsorption was between 70
and 80% (29).
Microneedles
Two types of microneedle arrays were used. Assembled
metal microneedle arrays with a length of 300 µm (300A)
were manufactured from commercially available 30G
hypodermic needles (30). 30G needles have a diameter of
300 µm at the base and a tapered shaft of approximately
1.2 mm, thereby forming an angle of approximately 15°.
These microneedles were positioned in a 4×4 pattern in a
polymer mould (diameter 5 mm) with a pitch of 1.25 mm.
The second type of array consists entirely of stainless steel,
and the microneedles were prepared by electrical dis-
charge machining (300ED). Similar as the 300A, the
300ED microneedles are 300 µm long and are positioned
in a 4×4 pattern with a pitch of 1.25 mm. They differ
from the 300A microneedles in shape, as can be observed
in Fig. 1. They have a square base of 250×250 µm, and
the tip of the microneedles is less sharp than that of the
300A microneedles. The shape of the tip is defined by a
diagonal plane which runs from the top of one side of the
square pillar to the opposed bottom, in this way forming
an angle of approximately 40° relative to the bottom
surface. An electrical applicator was used to apply the
microneedles with a speed of 3 m/s to ensure reproducible
piercing of the skin (25).
Immunisation Studies
The immunogenicity of the DT-loaded TMC nano-
particles and TMC/DT mixtures was assessed in an
immunisation study in mice using the two types of
microneedle arrays. The microneedle arrays were ap-
plied on the abdominal skin under anaesthesia (by
intraperitoneal injection of 150 mg/kg Ketamine and
10 mg/kg Xylazine). The microneedles were applied in
two ways: either before or after application of the
formulations. In both cases, 70 µl of the formulations
containing 100 µg DT were applied on the skin for 1 h
(∼2 cm2 area restricted by a metal ring). After the
application, the skin was washed with lukewarm water to
remove the remaining amount of formulation. Groups of
8 mice were vaccinated thrice with a three-week interval.
To circumvent the skin barrier, the formulations (5 µg
DT/30 µL formulation) were also injected ID with a
Hamilton syringe equipped with a 30G needle as
described before (15). As a positive control, DT-alum
(5 µg DT and 150 µg alum/100 µL) was injected
subcutaneously (SC). In some groups CT was used as an
additional adjuvant: 10 µg per mouse for ID 100 µg for
the microneedle groups. One day before each immunisa-
tion blood samples were collected from the tail vein.
Three weeks after the last vaccination the mice were
sacrificed. Just before euthanasia total blood was collected
from the femoral artery. Blood samples were collected in
MiniCollect® tubes (Greiner Bio-one, Alphen a/d Rijn,
The Netherlands) until clot formation and centrifuged
10 min at 10,000 g to obtain cell-free sera. The sera were
stored at−80°C until further use.
Detection of Serum IgG, IgG1 and IgG2a
DT-specific antibodies (IgG, IgG1 & IgG2a) in the sera
were determined by sandwich ELISA as described previ-
ously (27). Briefly, plates were coated overnight with 140 ng
DT. After blocking, two-fold serial dilutions of sera from
individual mice were applied to the plates. HRP-conjugated
antibodies against IgG were added and detected by TMB.
Antibody titres were expressed as the reciprocal of the
sample dilution that corresponds to half of the maximum
absorbance at 450 nm of a complete s-shaped absorbance-
log dilution curve.
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Vero Cell Test
The levels of diphtheria toxin-neutralising antibodies in
mouse sera were assessed by a Vero cell test as described
previously (31). Control samples included were reference
anti-serum and untreated cells. The plates were incubated
at 37°C in 5% CO2 for 6 days, and afterwards the presence
of living cells was verified by light microscopy. The
neutralising antibody titres were obtained from the serum
dilution factor that still resulted in living cells.
Analysis of In Vivo Transport into the Skin by Confocal
Microscopy
To visualise the transport into the skin of TMC
nanoparticles compared to a TMC solution, hairless
(skh-1) mice were treated with empty rhodamine-
labelled TMC nanoparticles or a TMC solution. In this
case, the 300A microneedles were used, and the mice
were pre-treated with the microneedles before occlusive
application of the formulations. An equal concentration
of rhodamine-labelled TMC was used in both formula-
tions, as determined by fluorescence spectroscopy
(FS920 fluorimeter, Edinburgh Instruments, Campus
Livingston, UK). After 1 h of application, the
formulations were removed with a cotton bud. To
visualise the distribution of the nanoparticles and
solution in the skin, the formulations were also injected
ID. After the mice were euthanised, the treated skin
area was removed, immediately mounted on a sample
holder and visualised with a confocal laser scanning
microscope. Images were taken every 10 µm, over a
total depth of 300 µm. Images were processed using a
Bio-Rad Radiance 2100 confocal laser scanning system
equipped with a Nikon Eclipse TE2000-U inverted
microscope and either a 4X plan fluor or a 10X plan
air objective (Nikon, Japan). The images were captured
using a helium neon laser at 543 nm, with a 570 long
pass emission filter. Image acquisition was controlled
using the Laser Sharp 2000 software (Bio-Rad, Hercu-
les, USA). The amount of TMC in the conduits was
estimated from the images using Image J (National
institute of health, USA). The distribution area of TMC
was calculated by the number of pixels in the specified
area containing a level of fluorescence above the
threshold value. Threshold settings were 20 AU (lower
Fig. 1 The two types of microneedles used in this study. A: Array of 300A microneedles, manufactured from commercially available 30G needles. B:
Array of 300ED microneedles, made of stainless steel. Both arrays contain sixteen microneedles with a length of 300 µm. In figure C and D higher
magnification images of a single 300A microneedle (C) and a 300ED microneedle (D) are shown.
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threshold) and 255 (upper threshold). A fluorescent
intensity below 20 AU was regarded as background
fluorescence.
Statistical Analysis
Statistical analysis was performed with Prism 5 for
Windows (Graphpad, San Diego, USA). Data are pre-
sented as mean ± SD for the immunisation studies and as
mean ± SEM for the confocal results. Statistical signifi-
cance was determined by a two-way analysis of variance
(ANOVA) with a Bonferroni post-test. The results of the
Vero cell test were analysed by a Kruskal-Wallis test with a
Dunn’s multiple comparison post-test.
RESULTS
Physicochemical Characteristics of the Formulations
DT-loaded TMC nanoparticles were prepared with a mean
size of 211±4 nm and a PDI of 0.15±0.01. They were
positively charged (zetapotential 12.9±0.8 mV in 10 mM
sodium phosphate pH 7.4), and the loading efficiency of
DT in the nanoparticles was about 70%. In the TMC/DT
mixtures, ~50% of the DT was adsorbed to the TMC,
which is likely due to the fact that TMC and DT carry
opposite charges at pH 7.4 (15). As reported previously, the
release of the antigen from the nanoparticles in PBS was
characterised by an immediate burst without any further
release over the next 9 days (15).
Combining Microneedles and Nanoparticles
for Transcutaneous Vaccination
In Fig. 2A, the anti-DT IgG titres after application of the
300A microneedles are shown. By applying a solution of
DT on microneedle pre-treated skin, an immune response
was initiated, with IgG titres 100-fold higher compared to
application of DT on intact skin (27). Still, these titres were
significantly lower compared to those obtained after SC
application of DT-alum, the positive control. Formulating
DT into TMC nanoparticles did not further increase the
immune response. In contrast, when a mixture of TMC
and DT solutions was applied on microneedle-pre-treated
skin, the IgG titres after the second boost were 8-fold higher
compared to application of a solution of DT (p<0.001) and
comparable to those elicited by SC DT-alum. Similar
results were obtained for the neutralising antibody titres
(Fig. 2B): after the second boost with a TMC/DT mixture,
a clear trend of enhanced titres compared to a solution of
DT were observed, whereas nanoparticles did not enhance
the titres. The titres after application of the TMC/DT
mixture, were not significantly different from those elicited
by SC DT-alum (p=0.26).
It was thought that by applying the formulation before
microneedle treatment, the microneedles might carry the
formulation with them into the skin (Fig. 2A). This
application method indeed induced higher IgG titres after
the first boost (p<0.01), but the IgG and neutralising
antibody titres after the second boost did not differ
significantly from those obtained after the original sequence
of application, i.e. microneedle treatment prior to applying
the nanoparticles. This indicates that both methods of
microneedle application result in similar immunogenicity.
Because the dose is more controlled when the formulations
are applied after microneedle pre-treatment, it was decided
to continue with this application method in the following
studies.
To investigate the effect of the shape of the microneedle
array, two different arrays were used: the 300A and the
300ED. Even though the microneedle arrays differ in shape
and sharpness (Fig. 1), similar IgG and neutralising anti-
bodies were observed after pre-treatment using either of the
two arrays (Fig. 3).
To further potentiate the immunogenicity of the for-
mulations, CT was added to the nanoparticles. Fig. 3A
shows that addition of CT, as compared to nanoparticles
alone, significantly enhanced the IgG titres after the prime
and two subsequent booster vaccinations (p<0.001). The
titres obtained after the second boost were comparable to
those after SC DT-alum immunisation. The results of the
neutralising antibody assay confirmed these results
(Fig. 3B). Furthermore, CT not only had an effect on the
total IgG titres, but also affected the IgG1/IgG2a ratio.
After immunisation with DT and TMC, mainly IgG1 titres
were induced (Fig. 3C), which is indicative of a Th2-biased
response (32,33). The addition of CT to the nanoparticle
formulations increased the IgG2a titres significantly (p<
0.01), pointing to a more Th1-skewed response.
ID Immunisation with TMC-Based Formulations
In transcutaneous immunisation, the transport of topically
applied vaccine into the skin could be an important barrier to
delivery of the vaccine to the APCs in the skin. To eliminate
this transport factor, the formulations were injected ID. In
Fig. 4 the antibody titres are shown after ID injection of mice
with a DT solution, a TMC/DT mixture and DT-loaded
TMC nanoparticles with and without CT. In line with a
previous study (15), the TMC nanoparticles resulted in
significantly higher IgG titres compared to those elicited after
ID injection of a DT solution (Fig. 4A), and higher
neutralising antibody titres were also observed (Fig. 4B).
DT-loaded TMC nanoparticles and TMC/DT mixture
induced comparable antibody titres, and the levels were not
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significantly different from those obtained after SC immuni-
sation with DT-alum (Fig. 4A,B). When CT was added to the
nanoparticle formulation, it accelerated and potentiated the
immune response (Fig. 4A). Higher IgG titres were obtained
compared to the SC DT-alum control after the prime and
first boost (p<0.01). Furthermore, after the second boost, the
addition of CT induced significantly higher neutralising
antibody titres (p<0.05) compared to plain DT (Fig. 4B).
After ID immunisation with all formulations the main IgG
subtype produced was IgG1, but the DT-loaded TMC
nanoparticles enhanced the production of IgG2a antibodies
(p<0.01). For the CT-containing formulation, the IgG2a
response was most pronounced (p<0.001).
Visualisation of TMC Transport into Skin
Fig. 5 shows representative images of the transport of
fluorescently labelled TMC nanoparticles and a TMC
solution into the microneedle conduits. With confocal
microscopy, easily all conduits could be visualised
(Fig. 5A), indicating that piercing with the microneedle
arrays was successful. In the conduits, fluorescence was
present in the deeper layers of the skin, until a depth of
approximately 150 µm (Fig. 5B). This image also illustrates
the shape of the conduits. Higher magnification images of
single conduits were also made (see Fig. S1, Supplementary
Material). The images show that at the skin surface, adjacent
to the conduits, fluorescence was observed in the furrows.
Deeper in the skin, the dye was solely present in the conduits.
The fraction of the TMC-rhodamine that will be transported
into the skin through the conduits is small. To compare the
transport into the skin of both formulations, the area
containing measurable dye fluorescence and the fluorescent
intensity were calculated from the images. In Fig. 6, the area
containing TMC-rhodamine is plotted against the skin
depth. The maximum area of TMC-rhodamine (solution
and nanoparticles) was not found at the surface, but at a
depth of 20–30 µm in the skin. When TMC-rhodamine was
applied in solution, it was distributed over a larger area in
the skin compared to application of TMC-rhodamine
nanoparticles. The distribution areas differ significantly at a
depth of 30–70 µm (p<0.05), indicating a broader distribu-
tion of the TMC-rhodamine solution. No difference in the
penetration depth was observed between the TMC-
rhodamine solution and TMC-rhodamine nanoparticles.
Images were also taken after ID injection of rhodamine-
labelled TMC (Fig. 7). In this case, the fluorescence could be
observed over a depth of 200 µm. It is evident that the TMC
is distributed over a much larger area when applied as a
solution (Fig. 7A) than in nanoparticulate form (Fig. 7B).
DISCUSSION
A combination of microneedles with adjuvants imple-
ments the two main requirements for effective minimally
invasive transcutaneous immunisation: increased trans-
port across the stratum corneum and induction of a
protective immune response. Both the microneedles and
the TMC-based formulations have already proven their
effectiveness in previous in vivo studies (15,27,28). More-
over, because of the positive charge of the TMC, it easily
forms complexes with the negatively charged antigen DT
and can induce maturation of DCs in vitro (15). The potent
adjuvant effect of TMC in the skin is clearly shown after
ID injection. Both the TMC/DT mixture and the TMC
Fig. 2 IgG (A) and neutralising antibody (B) titres obtained after piercing with 300A microneedles followed by application of a DT solution, a TMC/DT
mixture or DT-loaded TMC nanoparticles (TMCNP) as compared to SC DT-alum.A: IgG titres after prime and two booster vaccinations. Mean and SD of
8 mice. B: Neutralising antibody titres after second boost. Data are expressed as the highest dilution that was still capable of protecting the Vero cells
against challenge with diphtheria toxin. ** p<0.01, *** p<0.001.
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nanoparticles induced an equally strong immune re-
sponse, eliciting similar titres as after SC DT-alum
administration.
Besides ID immunisation, microneedle-based applica-
tion of a TMC/DT mixture also increased the antibody
titres compared to the application of a DT solution.
However, topically applied DT-loaded TMC nanopar-
ticles were not able to enhance the immune response.
The method of microneedle application or the type of
microneedle array used could not improve the immuno-
genicity of the TMC nanoparticles. Similarly, as ob-
served with the TMC nanoparticles, positively charged
liposomes also failed to enhance the immune response
against DT after microneedle pre-treatment (34). Even
though nanoparticles are mentioned as a promising tool
for transcutaneous vaccination (9), their usage so far is
limited. Studies focussed on the transport of different types
of nanoparticles across intact skin have shown that, in
most cases, the nanoparticles remain in the stratum
corneum or the hair follicles (35–37). The few groups that
claim successful penetration of nanoparticles into the skin
either lack an adequate explanation of the discrepancies
found for the transport of nanoparticles differing in size
and charge (38) or could not demonstrate whether the
nanoparticles themselves or only the released dye pene-
trates the skin (39). Lipid-based vesicles, which are thought
to penetrate the skin more easily, were shown to remain in
the stratum corneum (40–42). From these studies, it can be
concluded that, for successful delivery of nanoparticles
into the skin, the stratum corneum barrier needs to be
breached. Our group reported for the first time the in vitro
visualisation of transport of commercially available
Fig. 3 Effects of microneedle array type and co-administration of CTon the immunogenicity of the DT-loaded TMC nanoparticles (TMCNP) after microneedle
pre-treatment. A: IgG titres after prime and 2 booster vaccinations. B: Neutralising antibody titres after 2nd boost. Data are expressed as the highest dilution
that was still capable of protecting the Vero cells against challenge with diphtheria toxin. C: IgG1 and IgG2a titres after 2nd boost. A/C: Mean and SD of
8 mice. B: Individual values and geometric mean of 8 mice are shown. * p<0.05, ** p<0.01, *** p<0.001.
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Fig. 5 Representative images of microneedle conduits in mouse skin. A: x,y image (parallel to skin surface) showing 8 conduits at the skin surface. B: x,z
image (perpendicular to the skin surface) showing penetration of TMC-rhodamine until a depth of approximately 150 µm.
Fig. 4 IgG (A) and neutralising antibody (B) titres after ID vaccination with the different formulations. A: IgG titres after prime and 2 booster vaccinations.
B: Neutralising antibody titres after 2nd boost. Data are expressed as the highest dilution that was still capable of protecting the Vero cells against challenge
with diphtheria toxin. C: IgG1 and IgG2a titres after 2nd boost. A/C: Mean and SD of 8 mice. B: Individual values and geometric mean of 8 mice are
shown. • significantly higher compared to ID DT. ‡ significantly higher compared to SC DT-alum. * p<0.05, ** p<0.01.
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polymeric nanoparticles with a size of 200 nm into human
skin after pre-treatment with the 300A microneedles (30).
The nanoparticles could be traced until a depth of
approximately 250 µm. These results were confirmed by
Coulman et al., who pre-treated the skin with 280-µm-long
microneedles and showed that nanoparticles with a size of
138 nm were able to penetrate into the epidermis (43). To
further investigate the transport of TMC nanoparticles
and a TMC solution, visualisation studies were performed.
We visualised ex vivo the transport of positively charged
TMC nanoparticles into the skin. We showed that these
nanoparticles could be transported through the micro-
needle conduits, though to a lower extent compared to the
polymer in solution. The conduit area containing TMC-
rhodamine was larger for the solution than for the
nanoparticles, indicating a broader distribution of the
TMC solution. A possible reason for this is blockage of
the conduits due to the electrostatic interactions between
the positively charged nanoparticles and the negatively
charged skin. Also, the presence of proteins may cause
aggregation of the nanoparticles, making the transport of
the nanoparticles through the conduits to the APCs an
important limiting factor. It should be noted that by
prolonging the application time of the formulations (>1 h),
the transport might be boosted.
The addition of an additional adjuvant (CT) to the
nanoparticles increased the IgG and neutralising antibody
titres after microneedle pre-treatment, reaching similar
IgG levels as after SC immunisation with DT-alum. It is
worthwhile to mention that next to enhanced total
antibody levels, addition of CT also induced substantially
higher IgG2a titres and, hence, affected the IgG1/IgG2a
ratio, both after ID and after transcutaneous application.
This is in agreement with other transcutaneous immuni-
sation studies performed with DT (28), the cross-reacting
material (CRM197) of diphtheria toxin (44) and inactivated
influenza virus (45). Elevated IgG2a titres could be
beneficial in case of vaccination against viruses or intracel-
lular bacteria, where a more Th1-biased response is
required.
For DT, high IgG1 rather than IgG2a titres seem to
correlate with protection (28,46). In our studies, vaccina-
tion with DT mainly results in the production of IgG1
antibodies, indicating a Th2-biased, response as is usually
reported for toxins (47). After transcutaneous immunisa-
tion, TMC strengthened this Th2 bias, in agreement with
our in vitro studies on human monocyte derived DCs and
T cells (14,15). Contrarily, after ID administration, both
TMC formulations enhanced significantly the production
of IgG1, but even more that of IgG2a. This could be
explained by the fact that after ID injection the formula-
tions will reach the dermis, while with the microneedles
also the epidermis is targeted. Previous studies in mice
have shown that by immunising via the epidermis mainly a
Th2-biased response is elicited (48–51). It is thought that
Fig. 7 X,y images (parallel to the skin surface) showing the distribution pattern in the dermis after ID injection of either a TMC-rhodamine solution (A) or
TMC-rhodamine nanoparticles (B).
Fig. 6 Determination of the fluorescence in the skin after microneedle
pre-treatment and application of either TMC-rhodamine nanoparticles or
a TMC-rhodamine solution. Area containing fluorescence plotted against
the skin depth. Mean and SEM of 3 mice.
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in these cases the immune response is initiated mainly by
epidermal LCs that take up the antigen and migrate to the
lymph nodes (51). In addition, Klechevsky et al. showed
that human LCs upon stimulation with CD40L efficiently
induced the secretion of Th2 type cytokines by T cells (52).
In the dermis of mice, two types of DCs are present: the
classical dermal DCs and a recently discovered langerin+
DCs (53–55). This subtype differs from LCs and the
classical dermal DCs by a low expression of CD11b and
high expression of CD103. The exact role of these dermal
langerin+ CD11b−CD103+ DCs in the humoral immune
response is not clear yet, but the presence of different DC
subtypes in the epidermis and dermis could explain the
different immune response generated after transcutaneous
and ID immunisation.
CONCLUSION
For successful transcutaneous immunisation, both the
transport into the skin and the activation of the APCs are
important. This can be achieved by the combination of
microneedles and an adjuvant. TMC offers great promise
as an adjuvant for transcutaneous immunisation, but not
when formulated in nanoparticles. Nanoparticles, which are
much smaller, might be more suitable to use in combination
with microneedle arrays. Moreover, as this study showed that a
mixture of TMC and DT is able to increase the immunoge-
nicity, conjugation between the polymer and the antigen could
be a better option to further potentiate the immune response
(56), also via the transcutaneous route.
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